Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe page revision indicator changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedFooter/site metadata updated: Revision v3.3.3 added; HHS Vulnerability Disclosure link removed and Revision v3.3.2 removed, with no impact on study content or user actions on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page shows an updated revision from v3.3.1 to v3.3.2, indicating a minor update to the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedAdded revision label v3.3.1 and removed revision label v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedFunding-status notice at the bottom of the page was removed. The core study content, including objectives, eligibility criteria, and outcome measures, remains unchanged.SummaryDifference0.4%

- Check73 days agoChange DetectedNo significant changes detected between the two page states; only minor visual differences are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.